The Working Group on Health Policy deals with business and political parameters, ranging from licensing, paths to reimbursement, market access and care to billing for biopharmaceutical products. More broadly, its work also involves analysing the business policy and health economy policy issues of the legal parameters for Germany as a biotech location.
|Prof. Dr. Helga Rübsamen-Schaeff||AiCuris Anti-infective Cures GmbH|
|Prof. Dr. med. Niels Riedemann||InflaRx GmbH|